View Older Stories View More Recent Stories

Jul 21, 2025 08:02AM Johnson & Johnson submits FDA application for psoriasis drug icotrokinra
Jul 17, 2025 10:29AM Johnson & Johnson (JNJ) PT Raised to $185 at RBC Capital
Jul 17, 2025 09:32AM Johnson & Johnson (JNJ) PT Raised to $190 at UBS
Jul 17, 2025 08:01AM Johnson & Johnson gets FDA priority review for bladder cancer treatment
Jul 17, 2025 07:22AM Johnson & Johnson (JNJ) PT Raised to $167 at Guggenheim
Jul 17, 2025 06:07AM Johnson & Johnson (JNJ) PT Raised to $185 at Goldman Sachs
Jul 16, 2025 03:19PM Johnson & Johnson (JNJ) PT Raised to $165 at Stifel
Jul 16, 2025 06:21AM Johnson & Johnson (JNJ) Tops Q2 EPS by 9c, Beats on Revenue; Offers Strong FY25 Guidance
Jul 16, 2025 06:21AM Stocks expected to have increasing option volume: MS GS BAC JNJ PNC PGR
Jul 16, 2025 02:00AM Johnson & Johnson earnings preview Q2: flat print expected, tariff impact in focus
Jul 15, 2025 11:20AM Johnson & Johnson (JNJ) call put ratio 1.7 calls to 1 put into quarter results
Jul 15, 2025 06:30AM Johnson & Johnson (JNJ) call put ratio 1.2 calls to 1 put into quarter results
Jul 10, 2025 06:15AM Wolfe Research Reiterates Outperform Rating on Johnson & Johnson (JNJ)
Jul 10, 2025 06:02AM Goldman Sachs Reiterates Conviction Buy Rating on Johnson & Johnson (JNJ)
Jul 8, 2025 08:03AM Johnson & Johnson submits FDA application for CAPLYTA schizophrenia use
Jun 23, 2025 07:32AM Johnson & Johnson (JNJ) reports IMAAVY showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis
Jun 20, 2025 08:17AM Johnson & Johnson (JNJ) says IMBRUVICA received positive CHMP opinion for the treatment of patients with previously untreated MCL
Jun 13, 2025 11:00AM Johnson & Johnson (JNJ) says dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Jun 12, 2025 04:10PM Kenvue (KVUE) considers selling skin health and beauty brands, sources say - Reuters
Jun 12, 2025 11:00AM Johnson & Johnson (JNJ) says bleximenib demonstrated promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Jun 11, 2025 08:05AM Johnson & Johnson (JNJ) Reports New guselkumab showing its significantly inhibits progression of joint structural damage in active psoriatic arthritis
Jun 10, 2025 04:52PM Johnson & Johnson (JNJ) Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
Jun 3, 2025 10:47AM Johnson & Johnson's (JNJ) DARZALEX FASPRO shows strong data
Jun 3, 2025 10:46AM Johnson & Johnson (JNJ): Single infusion of CARVYKTI delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
Jun 3, 2025 10:46AM Johnson & Johnson (JNJ) announces promising early results from TsAb
May 20, 2025 07:30PM Johnson & Johnson (JNJ) FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO
May 20, 2025 11:04AM FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
May 13, 2025 03:01PM Johnson & Johnson (JNJ) call put ratio 1 call to 1 put as share price down 3.1%
May 13, 2025 08:55AM Leerink Partners Downgrades Johnson & Johnson (JNJ) to Market Perform
May 9, 2025 08:05AM Johnson & Johnson (JNJ) reports Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
May 7, 2025 05:27AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.5 puts
May 5, 2025 08:06AM Johnson & Johnson (JNJ) says TREMFYA positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
May 5, 2025 08:05AM Johnson & Johnson (JNJ) says TREMFYA delivered sustained clinical and endoscopic remission in ulcerative colitis through two years
May 1, 2025 05:24AM Goldman Updating US May Directors' Cut Conviction List Names
Apr 30, 2025 08:29AM Johnson & Johnson (JNJ) receives FDA approval for IMAAVY
Apr 28, 2025 11:34AM HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
Apr 26, 2025 04:00AM Medtech Q1 earnings preview: Potential tariff exposure
Apr 21, 2025 09:39AM Johnson & Johnson (JNJ) unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
Apr 16, 2025 11:08AM TD Cowen: 'Johnson & Johnson (JNJ) Is Prepared to Absorb Tariff Costs'
Apr 16, 2025 09:58AM UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
Apr 15, 2025 06:41AM Johnson & Johnson (JNJ) Tops Q1 EPS by 19c; adjusts forecast
Apr 15, 2025 06:28AM Johnson & Johnson (JNJ) Raises Quarterly Dividend 4.8% to $1.30; 3.4% Yield
Apr 15, 2025 04:00AM Analysts brace for volatile Johnson & Johnson Q1 amid Part D impact, legal setbacks
Apr 14, 2025 10:28AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.4 puts into quarter results
Apr 14, 2025 06:10AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.3 puts into quarter results
Apr 9, 2025 09:19AM Pharma stocks slide after Trump signals tariffs on sector
Apr 8, 2025 06:16AM Johnson & Johnson (JNJ) highlights new data that showcase the strength of nipocalimab
Apr 8, 2025 05:07AM Goldman Sachs Upgrades Johnson & Johnson (JNJ) to Buy
Apr 4, 2025 10:47AM UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
Apr 4, 2025 08:05AM Johnson & Johnson (JNJ) announces TREMFYA significantly reduced both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
View More Recent Stories View Older Stories